Procalcitonin: A promising tool or just another overhyped test?

Area of Science:

• Critical Care Medicine
• Infectious Diseases
• Biomarker Research

Background:

• Sepsis is a leading global cause of mortality, necessitating prompt antibiotic treatment.
• Current diagnostic methods like microbiological cultures have limitations, including low sensitivity and delayed results.
• The search for ideal sepsis biomarkers with rapid turnover for timely diagnosis and treatment is ongoing.

Purpose of the Study:

• To review the history, pathophysiology, and clinical utility of procalcitonin (PCT) in sepsis diagnosis and management.
• To evaluate PCT's effectiveness in guiding antibiotic therapy initiation and discontinuation.
• To compare PCT with other sepsis biomarkers.

Main Methods:

• Literature review of studies on procalcitonin in sepsis.
• Analysis of clinical trial data and observational studies.
• Synthesis of information on PCT's diagnostic and prognostic value.

Main Results:

• Procalcitonin (PCT) aids in sepsis diagnosis and management, with FDA approval for guiding antibiotic treatment in certain infections.
• PCT has a good negative predictive value for bacterial infections, but its utility in initiating antibiotics is conflicting.
• PCT-guided antibiotic discontinuation reduces antibiotic duration, adverse effects, and overall mortality.

Conclusions:

• Procalcitonin is a valuable biomarker for managing sepsis, particularly for guiding antibiotic discontinuation.
• While PCT shows potential, its role in antibiotic initiation requires further investigation.
• PCT offers advantages over traditional methods, but its limitations must be considered in clinical practice.